Objectives: To evaluate tolerability and safety of estetrol (E4) 15 mg/drospirenone (DRSP) 3
mg oral contraceptive using pooled data from two, multicenter, phase 3 trials. Study design …

Objective To evaluate overall and subgroup efficacy of an estetrol (E4) 15 mg drospirenone
(DRSP) 3 mg oral contraceptive in a 24/4-day regimen. Study design We pooled efficacy …

Objective To assess efficacy, cycle control, and safety of an oral contraceptive containing
estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg. Study design Women aged 16 to 50 …

Objectives To assess the contraceptive efficacy, bleeding pattern and safety of a combined
oral contraceptive containing estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg. Design …

Purpose Despite considerable advances in recently developed combined oral
contraceptives (COCs), resulting in lower rates of adverse events while maintaining …

Introduction Estetrol (E4) is a native estrogen produced only by the fetal liver during
pregnancy. E4 is the first new estrogen to be used in hormonal contraception since the …

Objectives: This study evaluated acceptability, user satisfaction, body weight control and
general well-being of estetrol (E4) combined with either drospirenone (DRSP) or …

Objectives To evaluate the effect on endocrine and metabolic parameters of a new
combined oral contraceptive (COC) containing estetrol (E4) and drospirenone (DRSP) …

Estetrol/drospirenone is a combined oral contraceptive (COC) with a plant-synthesised
foetal oestrogen (estetrol) and a well-established progestin (drospirenone). In preclinical …

Ethinylestradiol and drospirenone combined oral contraceptive formulations have been
marketed for> 20 years. Drospirenone has antimineralocorticoid and anti-androgenic effects …